Bain, S., Sorli, C., Harashima, S., Tsoukas, G. M., Unger, J., Karsbøl, J. D., & Hansen, T. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), pp. 251-260. doi:10.1016/s2213-8587(17)30013-x

Bain, Steve, Christopher Sorli, Shin-ichi Harashima, George M. Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, and Thomas Hansen. "Efficacy and Safety of Once-weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-blind, Randomised, Placebo-controlled, Parallel-group, Multinational, Multicentre Phase 3a Trial." The Lancet Diabetes & Endocrinology 5, no. 4 (2017): 251-260.

Bain, Steve, et al. "Efficacy and Safety of Once-weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-blind, Randomised, Placebo-controlled, Parallel-group, Multinational, Multicentre Phase 3a Trial." The Lancet Diabetes & Endocrinology 5.4 (2017): 251-260.